Inhibitors of trehalose-6-phosphate synthase activity in fungal pathogens compromise thermal tolerance pathways
Abstract:
Infections caused by fungal pathogens such as Candida and Cryptococcus are associated with high mortality rates, partly due to limitations in the current antifungal arsenal. This highlights the need for antifungal drug targets with novel mechanisms of action. The trehalose biosynthesis pathway is a promising antifungal drug target because trehalose biosynthesis is essential for virulence in Cryptococcus neoformans and Candida albicans and is also a mediator of fungal stress responses, such as thermotolerance. To exploit its untapped antifungal potentials, we screened the St. Jude 3-point pharmacophore library to identify small molecule inhibitors of the first enzyme in the trehalose biosynthesis pathway, trehalose-6-phosphate synthase (Tps1). Structure-guided optimization of a potent hit, SJ6675, yielded a water-soluble inhibitor named 4456dh. Employing biochemical, structural and cell-based assays, we demonstrate that 4456dh inhibits Tps1 enzymatic activity, suppresses trehalose synthesis and exerts a fungicidal effect. Notably, the structure of Tps1 in complex with 4456 reveals that 4456 occupies the substrate binding pocket. Importantly, 4456dh renders normally thermotolerant fungal pathogens unable to survive at elevated temperatures, which is critical as we investigate the emergence of fungi from the environment due to a warming climate. Overall, this work develops the water-soluble 4456dh as an early-stage antifungal drug that has a distinct mechanism of action compared to existing clinical antifungals.
Importance:
The rise of fungal infections in recent years is alarming due to an increase in the vulnerable immunocompromised population, global temperature increase and limited antifungal treatment options. One of the major hurdles in developing new drugs is the identification of fungal-specific antifungal drug targets due to highly conserved cellular machinery between fungi and humans. Here, we describe a small molecule inhibitor, 4456dh, of the trehalose biosynthesis pathway. This pathway is present in fungi but not humans. Trehalose plays a critical role in stress responses such as thermotolerance in fungal pathogens and is essential for their virulence. We show that treatment with 4456dh blocks production of trehalose and renders fungal cells inviable. Thus far, 4456dh is active against two fungal pathogens of critical importance suggesting a broad-spectrum activity.
Insights
Researchers developed a new antifungal drug, 4456dh, targeting the trehalose biosynthesis pathway essential for fungal virulence. This novel compound inhibits trehalose-6-phosphate synthase (Tps1), offering a new strategy against deadly fungal infections.
Area of Science:
- Medical Mycology
- Medicinal Chemistry
- Drug Discovery
Background:
- Fungal infections caused by *Candida* and *Cryptococcus* species present significant mortality risks due to limited treatment options.
- Novel antifungal drug targets with distinct mechanisms of action are urgently needed.
- The trehalose biosynthesis pathway is crucial for fungal virulence and stress response, making it a promising target.
Purpose of the Study:
- To identify small molecule inhibitors of trehalose-6-phosphate synthase (Tps1), a key enzyme in the fungal trehalose biosynthesis pathway.
- To develop and characterize a novel, water-soluble antifungal agent targeting Tps1.
Main Methods:
- Screening of the St. Jude 3-point pharmacophore library to identify Tps1 inhibitors.
- Structure-guided optimization of a lead compound (SJ6675) to yield a water-soluble inhibitor (4456dh).
- Biochemical, structural, and cell-based assays to evaluate the inhibitor's efficacy and mechanism of action.
Main Results:
- Identification and optimization of 4456dh, a potent and water-soluble inhibitor of Tps1.
- Demonstration that 4456dh suppresses trehalose synthesis and exhibits fungicidal activity.
- Structural analysis revealed 4456dh binds to the Tps1 substrate-binding pocket, inhibiting its enzymatic activity.
- 4456dh effectively compromises the thermotolerance of fungal pathogens.
Conclusions:
- The developed compound 4456dh represents a promising early-stage antifungal drug candidate.
- 4456dh targets the trehalose biosynthesis pathway, offering a novel mechanism of action distinct from current antifungals.
- This research provides a new therapeutic avenue against life-threatening fungal infections, particularly relevant in the context of climate change-induced fungal emergence.
Related Concept Videos
Responses to Heat and Cold Stress
Riboswitches
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...


